Drugs targeting the renin-angiotensin-aldosterone system (Q34981356)

5 August 2017

1 reference

title

Drugs targeting the renin-angiotensin-aldosterone system (English)

1 reference

5 August 2017

Mohammad Amin Zaman

1

1 reference

PubMed ID

12402502

5 August 2017

Suzanne Oparil

series ordinal

2

1 reference

PubMed ID

12402502

5 August 2017

David A Calhoun

series ordinal

3

1 reference

5 August 2017

1 August 2002

1 reference

Nature Reviews Drug Discovery

5 August 2017

1 reference

5 August 2017

1

1 reference

5 August 2017

621-636

1 reference

5 August 2017

8

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd873

5 August 2017

0 references

cites work

Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989.

1 reference

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection

31 March 2020

1 reference

Angiotensin II receptor antagonists

31 March 2020

1 reference

The renin-angiotensin system (first of two parts).

31 March 2020

1 reference

Angiotensin receptors and their antagonists

31 March 2020

1 reference

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

31 March 2020

1 reference

Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases

31 March 2020

1 reference

Cloning and characterization of a human angiotensin II type 1 receptor

31 March 2020

1 reference

Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase.

31 March 2020

1 reference

Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation

31 March 2020

1 reference

Protection against ischemia: a physiological function of the renin-angiotensin system

31 March 2020

1 reference

Transient upregulation of the AT2 receptor mRNA level after global ischemia in the rat brain.

31 March 2020

1 reference

The angiotensin type 2 receptor: variations on an enigmatic theme

31 March 2020

1 reference

Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure.

31 March 2020

1 reference

Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation

31 March 2020

1 reference

Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells

31 March 2020

1 reference

Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries

31 March 2020

1 reference

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

31 March 2020

1 reference

Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function

31 March 2020

1 reference

Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1

31 March 2020

1 reference

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

31 March 2020

1 reference

Essential hypertension: renin and aldosterone, heart attack and stroke.

31 March 2020

1 reference

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

31 March 2020

1 reference

Cardiac angiotensinogen and its local activation in the isolated perfused beating heart

31 March 2020

1 reference

A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues

31 March 2020

1 reference

Contribution of circulating renin to local synthesis of angiotensin peptides in the heart

31 March 2020

1 reference

Angiotensin II-forming activity in a reconstructed ancestral chymase

31 March 2020

1 reference

Functional and biochemical analysis of angiotensin II-forming pathways in the human heart

31 March 2020

1 reference

Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces

31 March 2020

1 reference

Mineralocorticoid receptors and hypertension.

31 March 2020

1 reference

Extra-adrenal mineralocorticoids and cardiovascular tissue

31 March 2020

1 reference

Cardiac aldosterone production and ventricular remodeling

31 March 2020

1 reference

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

31 March 2020

1 reference

Inhibitors of renin as potential therapeutic agents

31 March 2020

1 reference

A BRADYKININ-POTENTIATING FACTOR (BPF) PRESENT IN THE VENOM OF BOTHROPS JARARCA

31 March 2020

1 reference

Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents

31 March 2020

1 reference

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

31 March 2020

1 reference

Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies

31 March 2020

1 reference

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction

31 March 2020

1 reference

Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group

31 March 2020

1 reference

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

31 March 2020

1 reference

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

31 March 2020

1 reference

Choosing the right ACE inhibitor. A guide to selection

31 March 2020

1 reference

Antihypertensive Therapy with MK 4211

31 March 2020

1 reference

Converting-enzyme inhibitors increase converting-enzyme mRNA and activity in endothelial cells

31 March 2020

1 reference

Bradykinin stimulates tissue plasminogen activator release in human vasculature

31 March 2020

1 reference

Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition

31 March 2020

1 reference

A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril

31 March 2020

1 reference

Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans

31 March 2020

1 reference

Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

31 March 2020

1 reference

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

31 March 2020

1 reference

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

31 March 2020

1 reference

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

31 March 2020

1 reference

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

31 March 2020

1 reference

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

31 March 2020

1 reference

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

31 March 2020

1 reference

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

31 March 2020

1 reference

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

31 March 2020

1 reference

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

31 March 2020

1 reference

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

31 March 2020

1 reference

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

31 March 2020

1 reference

Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators

31 March 2020

1 reference

An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.

31 March 2020

1 reference

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

31 March 2020

1 reference

The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan

31 March 2020

1 reference

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

31 March 2020

1 reference

Angiotensin II antagonists for hypertension: are there differences in efficacy?

31 March 2020

1 reference

Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.

31 March 2020

1 reference

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

31 March 2020

1 reference

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

31 March 2020

1 reference

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

31 March 2020

1 reference

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

31 March 2020

1 reference

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

31 March 2020

1 reference

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.

31 March 2020

1 reference

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

31 March 2020

1 reference

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

31 March 2020

1 reference

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

31 March 2020

1 reference

Efficacy and tolerance of spironolactone in essential hypertension.

31 March 2020

1 reference

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

31 March 2020

1 reference

31 March 2020

Resistant hypertension

1 reference

The role of spironolactone in the treatment of patients with refractory hypertension

31 March 2020

1 reference

31 March 2020

Vasopeptidase inhibitors

1 reference

Proposed update of angiotensin receptor nomenclature.

31 March 2020

1 reference

Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy

31 March 2020

1 reference

New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors

31 March 2020

1 reference

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

31 March 2020

1 reference

The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview

31 March 2020

1 reference

Antihypertensive drug therapy and survival by treatment status in a national survey

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD873

1 reference

5 August 2017

1 reference

PubMed ID

12402502